Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...

An international project into flu immunity could help develop better medications and vaccines to prevent severe disease.Imperial researchers will ...

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes.

New research from University of Iowa dispels the belief that pharmaceutical mergers lead to higher drug prices, showing a decrease in prices for generic drugs.

Award to support the development of molecules to inhibit BamA protein Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) will award a seed grant of US$610k to Justus Liebig ...

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop ...

UK Biobank has today announced the launch of the world’s most comprehensive study of the proteins circulating in our bodies, which will transform the study of diseases and their treatments.

Global spread of powdery mildew threatens blueberries, costing millions and prompting better disease management strategies.

Research on fungus spread could help growers predict, monitor and control powdery mildew disease affecting blueberries.

Brown-Forman's stock is a compelling investment with stable revenue and profit margins. Learn why BF.B is a Buy.